Related Experiment Video

Updated: Mar 20, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

'DE NOVO' Quantification of Genotype-Directed Therapy with Afatinib in Metastatic Lung Cancer

R Zaim1, L Tran2, H J M Groen3

  • 1Erasmus University, Institute for Medical Technology Assessment, Rotterdam, The Netherlands.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 21, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

Articles linked to this work by shared authors, journal, and citation graph.

Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.

European journal of nuclear medicine and molecular imaging·2026

Using kidney transplantation to explore epigenetic markers of frailty.

GeroScience·2026

The Coffee was Paid for Dearly: Shipwreck BZN4 and the Frigate't Hart.

Journal of maritime archaeology·2025

DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies.

Lung cancer (Amsterdam, Netherlands)·2025

Gut microbiome metagenomic sequences of honey bees (Apis mellifera) exposed to crops.

Microbiology resource announcements·2025

The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.

Lung cancer (Amsterdam, Netherlands)·2024

Cost-effectiveness of insulin regimens and insulin types for adults with type 1 diabetes: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Health Utilities and Costs for Multiple Sclerosis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Reconciling Conflicting Evidence on Peri-Immune Checkpoint Inhibitor COVID-19 mRNA Vaccination in Lung Cancer: A Time-Aligned Target Trial Emulation-Informed Landmark Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Assessing the Value of Digital Health Interventions: A Systematic Review of Evaluation Frameworks and Approaches, Key Dimensions and Criteria.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Evaluating the cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in intensive care: the UK-ROX trial.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Diabetes Status and the Association Between a Coronary Artery Disease Polygenic Risk Score and Incident Coronary Artery Disease in an Iranian Prospective Cohort.

Medical journal of the Islamic Republic of Iran·2026

AI-driven multi-omics biomarkers in precision breast cancer therapeutics: from discovery to clinical translation.

Frontiers in pharmacology·2026

FOXM1 Drives Subtype-Specific Dysregulation of Prognostic miRNAs in Breast Cancer Cells.

Journal of clinical practice and research·2026

Evaluation of Preoperative Factors Associated with Early Postoperative Neurological Outcome in the Treatment of Metastatic Spinal Tumors.

Indian journal of orthopaedics·2026

Molecular mechanisms and targeted therapeutic strategies for glycolytic reprogramming in osteosarcoma.

Genes & diseases·2026

Molecular and microenvironmental networks driving tumor dormancy: pathological mechanisms and emerging clinical strategies.

Frontiers in medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us